DK2829282T3 - Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning - Google Patents

Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning Download PDF

Info

Publication number
DK2829282T3
DK2829282T3 DK14182864.0T DK14182864T DK2829282T3 DK 2829282 T3 DK2829282 T3 DK 2829282T3 DK 14182864 T DK14182864 T DK 14182864T DK 2829282 T3 DK2829282 T3 DK 2829282T3
Authority
DK
Denmark
Prior art keywords
asn
samples
lys
adjuvant
ser
Prior art date
Application number
DK14182864.0T
Other languages
English (en)
Inventor
Theodore W Randolph
Amber Clausi
John F Carpenter
Daniel K Schwartz
Original Assignee
Univ Colorado Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents filed Critical Univ Colorado Regents
Application granted granted Critical
Publication of DK2829282T3 publication Critical patent/DK2829282T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (8)

1. Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning, hvilken fremgangsmåde omfatter: a. at kombinere mindst en aluminiumsaltadjuvans, mindst et succinatbuffer-system, mindst et glasdannende middel bestående af trehalose og et rekom-binant antigen, hvor antigenet er udvalgt eller stammer fra gruppen bestående af toksiner og vira, til dannelse af en flydende vaccineformulering; b. at lyofilisere den flydende vaccineformulering, hvor lyofiliseringen omfatter trinnene med: 1. at fryse den flydende vaccineformulering til dannelse af en frossen vaccineformulering; og ii. at tørre den frosne vaccineformulering til dannelse af en tørret vaccinesammensætning; hvor sammensætningen kan udløse en immunreaktion hos et individ.
2. Fremgangsmåde ifølge krav 1, hvor aluminiumsaltadjuvansen vælges fra gruppen bestående af aluminiumhydroxid, aluminiumphosphat og aluminiumsulfat.
3. Fremgangsmåde ifølge krav 2, hvor aluminiumsaltadjuvansen er aluminiumhydroxid.
4. Fremgangsmåde ifølge krav 1, hvor trehalose forekommer i en vægt til volumen-koncentration på fra 5 % til 20 % i den flydende vaccineformulering.
5. Fremgangsmåde ifølge krav 1, hvor trehalose forekommer i en vægt til volumen-koncentration på fra 7 % til 15 % i den flydende vaccineformulering.
6. Fremgangsmåde ifølge krav 1, hvor frysetrinnet omfatter en af bakkefrys-ning, hyldefrysning, spray-frysning, skalfrysning og nedsænkning i flydende nitrogen.
7. Fremgangsmåde ifølge krav 6, hvor frysetrinnet omfatter spray-frysning.
8. Fremgangsmåde til styring af partikelstørrelsen i en frossen vaccineformulering, hvilken fremgangsmåde omfatter: a. at blande mindst en adjuvans, hvor adjuvansen er aluminiumhydroxid, et glasdannende middel trehalose, der forekommer i en vægt til volumenkoncentration på fra 7 % til 15 %, og mindst et antigen, hvor antigenet er udvalgt eller stammer fra gruppen bestående af toksiner og vira i et succinatbuf-fersystem, til dannelse af en flydende vaccineformulering; og b. at lyofilisere den flydende vaccineformulering, hvor lyofiliseringen omfatter trinnene med: i. at afkøle den flydende vaccineformulering til en frossen tilstand til dannelse af en frossen vaccineformulering ved spray-frysning; og ii. at tørre den frosne vaccineformulering til dannelse af en tørret vaccinesammensætning; hvor den gennemsnitlige partikeldiameter af den rekonstituerede vaccinesammensætning efter optøning og fortynding af den tørrede vaccinesammensætning med et vandigt fortyndingsmiddel til dannelse af en rekonstitueret vaccinesammensætning er mindre end 10 mikrometer, hvor den gennemsnitlige partikeldiameter af den rekonstituerede vaccinesammensætning er en funktion af trehalosekoncentration.
DK14182864.0T 2007-03-22 2008-03-18 Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning DK2829282T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89642907P 2007-03-22 2007-03-22
EP08732401.8A EP2131857B1 (en) 2007-03-22 2008-03-18 Method of preparing an immunologically-active adjuvant-bound dried vaccine composition

Publications (1)

Publication Number Publication Date
DK2829282T3 true DK2829282T3 (da) 2018-01-02

Family

ID=39789236

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14182864.0T DK2829282T3 (da) 2007-03-22 2008-03-18 Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning
DK08732401.8T DK2131857T3 (da) 2007-03-22 2008-03-18 Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK08732401.8T DK2131857T3 (da) 2007-03-22 2008-03-18 Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning

Country Status (6)

Country Link
US (2) US8444991B2 (da)
EP (2) EP2829282B1 (da)
AU (1) AU2008231072B2 (da)
CA (1) CA2681567C (da)
DK (2) DK2829282T3 (da)
WO (1) WO2008118691A2 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
EA015964B1 (ru) * 2006-09-07 2012-01-30 Глаксосмитклайн Байолоджикалс С.А. Вакцина
US20110059079A1 (en) * 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
CA2699024C (en) 2009-11-06 2016-12-13 Intervet International B.V. Methods of immunizing pregnant heifers at three months of gestation
WO2011066390A2 (en) * 2009-11-25 2011-06-03 Wildcat Discovery Technologies, Inc. Nanoscale adjuvants and related pharmaceutical compositions and methods
GB2499480A (en) * 2010-03-31 2013-08-21 Stabilitech Ltd Method for preserving alum adjuvants and alum-adjuvanted vaccines
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
RU2012144612A (ru) 2010-04-15 2014-05-20 Син Ниппон Байомедикал Лэборэтэриз, Лтд. Способ и композиции для интраназальной доставки
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
CN103269716B (zh) * 2010-12-02 2015-05-27 昂科利蒂克斯生物科技公司 冻干病毒制剂
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
DK2709657T3 (da) * 2011-05-17 2019-01-14 Soligenix Inc Termostabile vaccine sammensætninger og fremgangsmåder til fremstilling deraf
US12447127B2 (en) 2011-05-17 2025-10-21 The Regents Of The University Of Colorado, A Body Corporate Thermostable vaccine compositions and methods of preparing the same
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
KR102049988B1 (ko) * 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
JP2015525748A (ja) * 2012-06-25 2015-09-07 エマージェント プロダクト デベロップメント ゲイザーズバーグ インコーポレイテッド 温度に安定なワクチン製剤
EP2934587A4 (en) * 2012-12-18 2016-08-03 Merck Sharp & Dohme Liquid formulations for an anti-TNF-alpha-antibody
US9732123B2 (en) 2013-03-15 2017-08-15 The Trustees Of The University Of Pennsylvania Mono or multivalent botulinum neurotoxin based vaccine using the heavy chain from serotypes of Clostridium botulinum
WO2014186754A2 (en) * 2013-05-16 2014-11-20 Board Of Regents The University Of Texas System Dry solid aluminum adjuvant-containing vaccines and related methods thereof
KR101398764B1 (ko) 2013-08-29 2014-05-27 강릉원주대학교산학협력단 입자의 이동에 의해 분석물질을 검출하는 장치 및 방법
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP6740127B2 (ja) * 2013-12-06 2020-08-12 ザ・ブロード・インスティテュート・インコーポレイテッド 新生物ワクチン用製剤
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
US10357559B2 (en) * 2013-12-27 2019-07-23 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
EP3139952A1 (en) * 2014-05-06 2017-03-15 The Regents of the University of Colorado, a body corporate Compositions, methods and uses for thermally stable human papillomavirus formulations
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
US10293041B2 (en) * 2014-07-09 2019-05-21 Soligenix, Inc. Multivalent stable vaccine composition and methods of making same
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP4636401A2 (en) 2014-12-19 2025-10-22 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
EP3270960A4 (en) * 2015-03-20 2018-08-08 Bluebird Bio, Inc. Vector formulations
CA2986235A1 (en) 2015-05-20 2016-11-24 The Broad Institute, Inc. Shared neoantigens
TWI750122B (zh) * 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
TW201718627A (zh) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
AU2017205690B2 (en) 2016-01-08 2022-04-28 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with increased NEP stability
CA3008017C (en) 2016-01-08 2024-01-02 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
US10751408B2 (en) 2016-02-23 2020-08-25 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for making and using thermostable immunogenic formulations with increased compatibility of use as vaccines against one or more pathogens
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
WO2018200991A1 (en) * 2017-04-28 2018-11-01 Bonti, Inc. Botulinum neurotoxins production methods
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
CA3079151A1 (en) 2017-10-16 2019-04-25 Serum Institute Of India Private Limited Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
US11918646B2 (en) 2017-12-11 2024-03-05 Board Of Regents, The University Of Texas System Dry adjuvanted immune stimulating compositions and use thereof for mucosal administration
EP3923906A1 (en) 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
WO2020236973A1 (en) 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
CN117208948B (zh) * 2023-09-18 2025-09-23 北京百晖生物科技有限公司 一种氢氧化铝佐剂的制备方法及其应用
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5855894A (en) * 1992-03-30 1999-01-05 Pfizer Inc. Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
JP3583128B2 (ja) 1993-01-08 2004-10-27 シーエスエル、リミテッド ワクチン製剤
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
ATE235919T1 (de) 1994-06-02 2003-04-15 Elan Drug Delivery Ltd Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen
JPH0840932A (ja) * 1994-07-29 1996-02-13 Kitasato Inst:The スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法
US6964771B1 (en) * 1995-06-07 2005-11-15 Elan Drug Delivery Limited Method for stably incorporating substances within dry, foamed glass matrices
EP1891968A3 (en) * 1996-09-26 2008-09-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
KR20030020294A (ko) 2000-06-08 2003-03-08 파우더젝트 백신, 인코포레이티드 분말 조성물
US6623762B2 (en) 2001-02-16 2003-09-23 Cambridge Biostability Ltd. Composition and method for controlled release injections
EP1399131A2 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions

Also Published As

Publication number Publication date
EP2131857A2 (en) 2009-12-16
AU2008231072A1 (en) 2008-10-02
US8444991B2 (en) 2013-05-21
EP2829282A1 (en) 2015-01-28
DK2131857T3 (da) 2015-09-14
CA2681567C (en) 2016-07-19
CA2681567A1 (en) 2008-10-02
AU2008231072B2 (en) 2013-08-01
US20100158951A1 (en) 2010-06-24
EP2131857B1 (en) 2015-07-29
WO2008118691A3 (en) 2008-12-18
EP2829282B1 (en) 2017-10-25
WO2008118691A2 (en) 2008-10-02
EP2131857A4 (en) 2011-07-20
US8808710B2 (en) 2014-08-19
US20130315966A1 (en) 2013-11-28
HK1206247A1 (en) 2016-01-08

Similar Documents

Publication Publication Date Title
DK2131857T3 (da) Fremgangsmåde til fremstilling af en immunologisk aktiv adjuvansbundet tørret vaccinesammensætning
US12097291B2 (en) Thermostable vaccine compositions and methods of preparing same
AU2017218989B2 (en) Thermostable vaccine compositions and methods of preparing same
HK1207312A1 (en) Temperature stable vaccine formulations
US12447127B2 (en) Thermostable vaccine compositions and methods of preparing the same
AU2013224715B2 (en) Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
HK1206247B (en) Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
HK40005815A (en) Thermostable vaccine compositions and methods of preparing same
NZ618319B2 (en) Thermostable vaccine compositions and methods of preparing same